TARA logo

Protara Therapeutics, Inc.

TARA
Healthcare|Biotechnology|US
$2.30
+0.17 (+7.98%)
DCF Value
$1.03
Tangible Book / Share
$2.24
Cash / Share
$2.02
Next Earnings Report
Mar 9, 2027
EPS est. -$0.38
Financing Filings (last 12 months)
7
Shelf registrations / offering prospectuses — latest May 28, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (4)

Dec 2026
Est. completion
P2Lymphatic Malformation
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age
NCT05871970n=38
Mar 2028
Est. completion
P2P3Choline Deficiency
Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support
NCT06910943n=129
Apr 2028
Est. completion
P3Bladder (Urothelial, Transitional Cell) Cancer
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
NCT07480356n=284
Oct 2031
Est. completion
P2Non-muscle Invasive Bladder Cancer
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
NCT05951179n=131

Recent Press Releases

Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update
Nov 6, 2026 · GlobeNewsWire
Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
Oct 15, 2026 · GlobeNewsWire
Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 8, 2026 · GlobeNewsWire

SEC Filings (77)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 6, 202610-QQuarterly reportDocumentIndex
Nov 6, 20268-KMaterial eventDocumentIndex
Aug 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 11, 2026S-8Employee stock planDocumentIndex
Aug 11, 202610-QQuarterly reportDocumentIndex
Aug 11, 20268-KMaterial eventDocumentIndex
Jul 7, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jun 29, 20268-KMaterial eventDocumentIndex
Jun 15, 20268-KMaterial eventDocumentIndex
May 28, 2026424B5Offering prospectusDocumentIndex
May 22, 2026EFFECTDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 14, 2026S-3Shelf registrationDocumentIndex
May 13, 202610-QQuarterly reportDocumentIndex
May 13, 20268-KMaterial eventDocumentIndex
Apr 28, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 28, 2026ARSAnnual report to holdersDocumentIndex
Apr 28, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 27, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 17, 2026PRE 14AProxy / shareholder voteDocumentIndex
Mar 30, 20268-KMaterial eventDocumentIndex
Mar 10, 202610-KAnnual reportDocumentIndex
Mar 10, 20268-KMaterial eventDocumentIndex
Mar 6, 2026424B7Offering prospectusDocumentIndex
Mar 2, 2026SC 13GPassive 5%+ stakeDocumentIndex
Feb 24, 20268-KMaterial eventDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 2, 2026424B7Offering prospectusDocumentIndex
Jan 21, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Dec 15, 20258-KMaterial eventDocumentIndex
Dec 9, 2025424B7Offering prospectusDocumentIndex
Dec 8, 20258-KMaterial eventDocumentIndex
Dec 5, 2025424B5Offering prospectusDocumentIndex
Dec 4, 2025424B5Offering prospectusDocumentIndex
Dec 3, 20258-KMaterial eventDocumentIndex
Nov 19, 20258-KMaterial eventDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 10, 202510-QQuarterly reportDocumentIndex
Nov 10, 20258-KMaterial eventDocumentIndex
Aug 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex